G
Genesis Therapeutics
Biotech & Life Sciences · Burlingame, United States · Founded 2019
Unifying AI and Biotech We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines MoreLess
Genesis Therapeutics is a biotech startup that leverages artificial intelligence (AI) to accelerate the development of new medicines. The company operates in the pharmaceutical industry, specifically in the drug discovery sector. Genesis Therapeutics uses a unique approach that combines 3D spatial graph modeling and advanced molecular simulation to generate potential drug candidates. This innovative method allows the company to explore untapped chemical spaces and unlock novel protein targets, which could lead to the discovery of critical new medicines.
The company's clients primarily include other biotech and pharmaceutical companies. For instance, Genesis Therapeutics has announced a discovery deal with Eli Lilly, a major pharmaceutical company. This deal involves an upfront cash payment of $20M, with the potential total value reaching up to $670M. This indicates that Genesis Therapeutics operates on a business-to-business model, where it provides its AI-driven drug discovery services to other companies in the industry.
Genesis Therapeutics makes money through these strategic partnerships and deals with other companies. The company receives upfront payments and potential future payments based on the success of the drugs discovered through its platform. In addition, Genesis Therapeutics has successfully raised significant funding through investment rounds, including a $200M Series B round co-led by Andreessen.
In summary, Genesis Therapeutics is a pioneering biotech startup that uses AI to discover and develop new drugs, serving other companies in the pharmaceutical industry through strategic partnerships.
Keywords: Biotech Startup, Artificial Intelligence, Drug Discovery, Pharmaceutical Industry, 3D Spatial Graph Modeling, Molecular Simulation, Strategic Partnerships, Investment Rounds, Andreessen, Eli Lilly.
Company overview
Genesis Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Burlingame, United States
- Employees
- 168
- Open positions
- 6
- Dealroom signal
- 88.7
Valuation & funding
Genesis Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $120M | $480M | Incyte | ↗ |
| LATE VCOther financing | Nov 2024 | $0 | — | NVentures | ↗ |
| SERIES BOther financing | Aug 2023 | $224M | $896M | Fidelity Investments · Rock Springs Capital · Radical Ventures · Andreessen Horowitz | ↗ |
| SERIES AOther financing | Dec 2020 | $52M | $208M | Andreessen Horowitz · Felicis · Menlo Ventures · Ulu Ventures | — |
| EARLY VCOther financing | Apr 2020 | $0 | — | Undisclosed | — |
| SPINOUTOther financing | Nov 2019 | Stanford University | — | ||
| SEEDOther financing | Nov 2019 | Andreessen Horowitz · Felicis | — |
Growth signals
Genesis Therapeutics website traffic
Latest recorded traffic for Genesis Therapeutics is 12K monthly website visits, down 14.3% over the last three months. Genesis Therapeutics's team grew 10.5% over the past year.
Hiring
Open positions at Genesis Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Genesis Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Genesis Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
18 investors on Genesis Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Genesis Therapeutics has talent and traffic
team presence
In the news
Latest news about Genesis Therapeutics
Recent press, funding announcements, and product moves mentioning Genesis Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Genesis Therapeutics
An AI-synthesized read of the highest-engagement posts about Genesis Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genesis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.